ALGOTX
14.3.2023 08:02:19 CET | Business Wire | Press release
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies’ Statement on Potential Transaction with Puig23.3.2026 21:15:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) confirms that it is in discussions regarding a potential business combination with Puig, in which the two companies would potentially merge their businesses. No final decision has been made, and no agreement has been reached. Unless and until an agreement is signed between the companies, there can be no assurances regarding the deal or its terms. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding a potential transaction and the anticipated timing, terms, and completion of any such transaction. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the possibility that no agreement will be reached, tha
Kinaxis Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ Reports for Supply Chain Planning23.3.2026 19:12:00 CET | Press release
Recognition based on company’s Completeness of Vision and Ability to Execute Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced it has been positioned as a Leader in both the 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for Discrete Industries and the 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for Process Industries. In both reports, Gartner recognized Kinaxis for its ability to execute and completeness of vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323129357/en/ Kinaxis Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ Reports for Supply Chain Planning: Discrete Industries Kinaxis has been recognized as a Leader in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for eleven times in a row. Kinaxis has also been recognized as a Leader in the 2026 Gartner Magic Quadrant for Supply Chain Planning Solutions
Armis Centrix™ Named “Best Solution” for Cyber Exposure Management as Armis Wins Multiple Global InfoSec Awards at RSAC 202623.3.2026 17:00:00 CET | Press release
Armis awarded “Publisher’s Choice Cybersecurity Company”Yevgeny Dibrov received “Industry Pioneering CEO” Armis, the cyber exposure management & security company, today announced that it has won multiple Global InfoSec Awards from Cyber Defense Magazine at this year’s RSAC™ Conference. Armis received the following accolades: Armis Centrix™ won “Best Solution” for Cyber Exposure Management Armis named “Publisher’s Choice Cybersecurity Company” Yevgeny Dibrov, Armis’ CEO and Co-Founder, awarded “Industry Pioneering CEO” “We cannot safeguard modern infrastructure with yesterday’s tactics; the extended attack surface demands a unified, AI-driven approach that sees, protects and manages all assets (IT, OT, IoT, IoMT, applications, code, cloud and AI) in real time,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Armis secures the most complex environments of organizations and governments worldwide to protect society from the destruction cybercriminals seek to cause. These awards reinforc
STOKR Appoints Subhankar Sinha as Senior Advisor23.3.2026 15:00:00 CET | Press release
Former BNY and PwC blockchain leader appointed to advance fund tokenization and STOKR's U.S. institutional expansion STOKR has appointed Subhankar Sinha as Senior Advisor. Sinha will work directly with STOKR's leadership team on fund tokenization with particular focus on money market fund (MMF) tokenization and on expanding STOKR's institutional presence in the U.S. market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323315236/en/ Image, Subhankar Sinha A New York-based digital assets executive, Sinha brings deep expertise across blockchain infrastructure, capital markets, and institutional business development. He previously served as Head of Blockchain at BNY, the world's largest custody and asset servicing business. Earlier in his career, he was a Director at PwC, where he co-founded and co-led the firm's blockchain consulting practice in the U.S. "Subhankar brings the institutional depth that this stage of STOKR's
Xsolla Partners With Cyprus Game Makers Association (CYGMA) as the Island Emerges as a Game Development Hub23.3.2026 14:00:00 CET | Press release
Strategic Partnership Equips Cyprus-Based Developers With the Commerce Infrastructure to Compete Globally Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a strategic partnership with the Cyprus Game Makers Association (CYGMA). The collaboration will provide creators and studios within the CYGMA network with hands-on support, industry expertise, and access to world-class commerce tools, helping Cyprus-based studios bring their titles to players worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323570679/en/ Graphic: Xsolla The partnership comes as Cyprus continues to attract game development talent, fueled by favorable business conditions and a growing creative community. Through its collaboration with CYGMA, Xsolla aims to accelerate momentum and expand opportunities for developers by removing commerce and distribution barriers that often p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom